Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2017 | (b) 2018 | (c) 2019 | (d) 2020 | (e) 2021 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 11,921,451 | 12,714,798 | 9,898,471 | 10,990,906 | 9,446,996 | 54,972,622 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.... | 0 | |||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | 0 | |||||
| 4 | Total. Add lines 1 through 3 | 11,921,451 | 12,714,798 | 9,898,471 | 10,990,906 | 9,446,996 | 54,972,622 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .. | 329,544 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 54,643,078 | |||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2017 | (b) 2018 | (c) 2019 | (d) 2020 | (e) 2021 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 11,921,451 | 12,714,798 | 9,898,471 | 10,990,906 | 9,446,996 | 54,972,622 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 296,562 | 308,859 | 270,568 | 222,444 | 276,878 | 1,375,311 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 284,518 | 259,968 | 301,733 | 192,317 | 135,298 | 1,173,834 |
| 11 | Total support. Add lines 7 through 10 | 57,525,273 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2017 | (b) 2018 | (c) 2019 | (d) 2020 | (e) 2021 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2017 | (b) 2018 | (c) 2019 | (d) 2020 | (e) 2021 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2021 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2021 |
(iii) Distributable Amount for 2021 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2021 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2021 (reasonable cause required-- explain in Part VI). See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2021: | ||||
| a From 2016....... | ||||
| b From 2017....... | ||||
| c From 2018....... | ||||
| d From 2019....... | ||||
| e From 2020....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2021 distributable amount | ||||
|
i
Carryover from 2016 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2021 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2021 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2021, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2021. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2022. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2017..... | ||||
| b Excess from 2018..... | ||||
| c Excess from 2019..... | ||||
| d Excess from 2020..... | ||||
| e Excess from 2021..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Go to www.irs.gov/Form990 for the latest information.
| Return Reference | Explanation |
|---|---|
| PART III, LINE 1 - ORGANIZATION'S MISSION: | The National Foundation for Cancer Research (NFCR) is a leading public charity dedicated to funding cancer research and public education relating to cancer prevention, earlier diagnosis, better treatments and, ultimately, cures for cancer. NFCR has distinguished itself in the cancer research sector by emphasizing long-term, transformative research often overlooked by other major funding sources. NFCR promotes and facilitates collaboration among scientists to accelerate the pace of discovery from bench to bedside. Since 1973, NFCR has provided more than $400 million in support of discovery-oriented cancer research focused on understanding how and why cells become cancerous, and on public education relating to cancer prevention, detection, and treatment. NFCR is committed to fighting cancer by funding high-risk, high-impact, and potentially high-reward discoveries in the labs and transforming them into life-saving treatments for cancer patients. Through global collaboration, NFCR is making unique impacts on new, accelerated paths to a cure. NFCR envisions a world without cancer! NFCR-FUNDED RESEARCHERS ARE MAKING PROGRESS EVERY DAY IN THEIR PURSUIT OF CANCER CURES, AND THIS IS ONLY POSSIBLE WITH THE FINANCIAL SUPPORT FROM OUR DONORS. ONE STEP AT A TIME, WE ARE GETTING CLOSER TO OUR ULTIMATE GOAL-CURING CANCER, ALL TYPES OF CANCER. FOR MORE INFORMATION, PLEASE VISIT WWW.NFCR.ORG. |
| PART III, LINE 4A - CANCER RESEARCH PROGRM ACCOMPLISHMENTS: | HIGHLIGHTS OF RESEARCH ACCOMPLISHMENTS ====================================== With support from our generous donors, NFCR-funded scientists have made numerous remarkable advances in the fight against cancer. Their research encompasses a wide variety of fields, many of which could ultimately lead to a cure for this deadly disease. Racial Disparity Research in Lung Cancer ---------------------------------------- Wei Zhang, Ph.D. found African American lung cancer patients have different mutations in key cancer-related genes than Caucasian patients, contributing to the increased incidence and lower survival rates in African Americans. The Zhang team won a larger national grant to study more patients, which may lead to life-saving treatments to reduce racial disparity in lung cancer survival rates. Predicting Why Cancer Spreads in Some Patients ---------------------------------------------- Danny Welch, Ph.D. is finding variabilities in the cell part that produces our body's energy, possibly explaining why cancer spreads in some patients but not in others. This may partially explain racial disparities in cancer rates and severity. His team's research suggests a simple blood test could guide doctors to aggressively treat patients whose cancer may spread, or spare patients at low risk from undergoing treatment side effects. Propelling Development of a New Immunotherapy --------------------------------------------- With NFCR discovery research funds, Paul Fisher, M.Ph., Ph.D. advanced his powerful immune-stimulating agent as a new treatment to stop the spread of different types of cancer. NFCR's AIM-HI Translational Research Initiative awarded additional support to bridge the gap between discovery research and expensive clinical drug development required for FDA approval. This year, the AIM-HI funds were matched from another non-profit. Together - we are propelling research forward, giving patients hope for a cure. Benefits of Tumor Microenvironment Research ------------------------------------------- Rakesh Jain, Ph.D. advanced his renowned research on the environment around tumors and our immune system. His team demonstrated exercise in breast cancer brings cancer-killing immune cells into tumors, resensitizing cancer to immunotherapy! They also applied a model for cancer therapy based on inflammation and the immune system - to make COVID-19 treatments more effective. These findings have significant implications for improving treatment efficacy and patient survival. Botanical Drug Treating Patients in Clinical Trials --------------------------------------------------- Over two decades of funding from NFCR supporters helped Yung-Chi Cheng, Ph.D. and his team develop YIV-906, a botanical drug with multiple anti-cancer properties that enhance immunotherapy and chemotherapy. NFCR's AIM-HI Translational Research Initiative support facilitated the translation of YIV-906 reach the clinical stages. Now, a global clinical trial is treating liver cancer patients with YIV-906 combined with a frontline drug. Since YIV-906 also protects the gastrointestinal tract from harsh side effects of many therapies, the botanical should alleviate adverse effects of the frontline drug that has caused many patients to discontinue its use. With success in final phase clinical trials, YIV-906 could become the first U.S.-approved botanical cancer drug-a remarkable achievement. Unique Clinical Trial Gives Hope to Brain Cancer Patients --------------------------------------------------------- A revolutionary clinical trial model, GBM AGILE, is now available to treat patients with the deadliest brain cancer, glioblastoma (GBM). Patients who have not had a new effective treatment in decades, now have hope for survival. GBM AGILE's unique design surpasses standard trials to efficiently evaluate multiple new drugs and drug combinations simultaneously. Benefits include lower cost, reduced time, and fewer patients required to evaluate potential new therapies. Three experimental therapies are available for "treatment arms" in GBM AGILE. In 2021, more than 35 U.S. cancer centers were open to treat patients in the U.S. and Canada. Trial expansion in Europe and China is underway. Since its opening in June 2019 UNITL END OF 2021, GBM AGILE trial has screened 965 patients into the treatment arms. Enrollment rates are 3 to 4 times greater than traditional GBM studies. NFCR has been a pioneer and founding supporter of GBM AGILE. We are also a strategic partner of the Global Coalition for Adaptive Research (GCAR), the official nonprofit sponsor of GBM AGILE. This uniquely designed clinical trial platform is now being utilized to rapidly test new treatments COVID-19 and in the future for other cancers. Launching New Research Program: Restoring Sight for Eye Cancer Patients ----------------------------------------------------------------------- Cancer can damage the eye's retina and cause blindness. With your support, NFCR is now funding the pioneering research of ophthalmologists, Dr. Jean Bennett and Dr. Katherine Uyhazi. Dr. Bennett developed the first FDA-approved gene therapy for a genetic disease, restoring retinal genes and vision in childhood blindness! Together, Drs. Bennett and Uyhazi will now use both gene and cell replacement therapy, two necessities to restore critical retinal components damaged in eye cancer. Your support will impact eye cancer patients as well as those with other eye diseases, giving new hope that their sight may be saved. New Treatment for Childhood Cancer ---------------------------------- Lack of therapies made specifically for young patients forces pediatric oncologists to use adult cancer drugs. In addition to debilitating side effects that can last a lifetime, there are many forms of childhood cancer whose outlook is poor. Unfortunately, financial investment to develop specific pediatric cancer drugs has been dismal. NFCR's AIM-HI Translational Research Initiative supports a pipeline to develop treatments for the most common pediatric cancers with the worst outcome. Volasertib is the pipeline's first drug and will soon reach clinical trials to treat rhabdomyosarcoma, a rare and deadly childhood cancer affecting 450 new patients yearly. Volasertib has the FDA Rare Pediatric Disease Designation to fast-track the drug approval process. Volasertib also has from the FDA Orphan Drug Designation (for diseases that affect less than 200,000 individuals) that provides tax credits to reduce clinical trial costs and a waiver of new drug application fees - saving developers of volasertib nearly $2.9 million dollars. These benefits will save precious time and money for patients, doctors and drug developers. Your commitment to funding this unmet medical need for better treatments is making a difference in the lives of children! NFCR'S CANCER PATIENT TREATMENT ASSISTANCE ------------------------------------------ A cancer diagnosis comes with panic, confusion, uncertainty and many questions: what tests should be scheduled, what are the best treatment options, and are there clinical trials for a new therapy that are suitable to the patient's cancer. NFCR understands the patient's frustrations and needs, and we provide assistance through the difficult time by linking a person in need with the Cancer Patient Treatment Assistance, where one may receive expert professional help from our oncologists. . Understanding the diagnosis and treatment options . Recommend top oncologists to meet specific needs and coordinate the referral process . Identify clinical trials of the newest therapies for advanced cancer or rare tumors for which no standard care or effective therapy is available This medical advice is provided as a resource for patients to consult with their medical team. |
| PART III, LINE 4B - CANCER PREVENTION EDUCATION TO THE PUBLIC: | NFCR provides the public with free materials containing valuable information on the most up-to-date cancer preventive measures, treatment options, and diagnostic tools. Our powerful message has been mailed annually to households, reaching over 266,000 email subscribers and tens of thousands of individuals through our social media channels (Twitter and Facebook) and through our website and blogs, helps to assure that fewer of today's healthy individuals will get cancer and more of today's cancer patients will become tomorrow's cancer survivors. Our public education materials include early cancer detection guide, cancer prevention kits, recipes for healthy living, electronic and printed newsletters, the latest cancer headlines, and in-depth online cancer information. |
| PART VI, SECTION A, LINE 4 - AMENDMENTS TO GOVERNING DOCUMENTS: | NFCR AMENDED THEIR BYLAWS IN 2021: 1. INCREASED THE TERM OF OFFICERS FROM ONE YEAR TO THREE YEARS. 2. ADDED TO LIST OF CORPORATE OFFICERS THE TITLE OF CHAIRPERSON AND VICE CHAIRPERSON. 3. THE CORPORATE OFFICERS SHALL BE CHOSEN ANNUALLY BY THE BOARD OF DIRECTORS EXCEPT FOR THOSE HOLDING POSITIONS AS PRESIDENT AND CHIEF EXECUTIVE OFFICER, THE EXECUTIVE VICE-PRESIDENT, AND CHIEF OPERATING OFFICER WHOSE TERMS ARE GOVERNED INSTEAD BY THEIR EMPLOYMENT WITH THE FOUNDATION. |
| PART VI, SECTION B, LINE 11B - REVIEW PROCESS OF FORM 990: | THE NATIONAL FOUNDATION FOR CANCER RESEARCH'S PROCESS FOR REVIEWING THE FORM 990. ======================================================================== 1. FORM 990 WILL BE PREPARED AFTER ANNUAL AUDIT IS DONE. 2. THE FIRST DRAFT WILL BE REVIEWED BY THE CHIEF OPERATING OFFICER AND THE CHIEF FINANCIAL OFFICER. 3. AFTER RESOLVING ANY QUESTIONS OR UPDATES, THE REVISED DRAFT WILL BE SENT TO BOARD MEMBERS, PREFERABLY ELECTRONICALLY FOR THEIR REVIEW AND COMMENTS. 4. THE BOARD MEMBER'S COMMENTS, IF ANY, WILL BE INCORPORATED IN THE FINAL RETURN. 5. THE RETURN WILL BE FILED WITH THE IRS PRIOR TO THE DESIGNATED DUE DATE OR EXTENDED DUE DATE. 6. THE STATE VERSION WILL BE PROVIDED TO STATES FOR REGISTRATION RENEWALS AND THE PUBLIC PORTIONS OF THE RETURN WILL BE POSTED ON THE FOUNDATION'S WEBSITE. 7. IN THE OCCASION THAT THERE IS INSUFFIENT TIME PRIOR TO FILING FORM 990 TO SHARE IT WITH THE BOARD, OR THERE IS ABSENCE OF AN OPPORTUNITY FOR ANY MEANINGFUL REVIEW OF FORM 990 BY THE BOARD PRIOR TO THE FILINGS DEADLINE, AN ELECTRONIC VERSION OF THE FILED RETURN WILL BE AVAILABLE FOR BOARD MEMBERS' REVIEW AND COMMENTS AFTER SUBMISSION OF RETURN TO IRS. AN AMENDED RETURN, IF NECESSARY, WILL BE FILED. |
| PART VI, SECTION B, LINE 12C - CONFLICT OF INTEREST POLICY COMPLIANCE: | EACH DIRECTOR, PRIOR TO TAKING HIS/HER POSITION ON THE BOARD, AND ALL PRESENT DIRECTORS SHALL SUBMIT IN WRITING TO THE CHAIRMAN OF THE BOARD A LIST OF ALL BUSINESSES OR OTHER ORGANIZATIONS OF WHICH HE/SHE IS AN OFFICER, DIRECTOR, TRUSTEE, MEMBER, OWNER SHAREHOLDER, EMPLOYEE OR AGENT, WITH WHICH THE FOUNDATION HAS, OR MIGHT REASONABLE IN THE FUTURE ENTER INTO, A RELATIONSHIP OR A TRANSACTION IN WHICH THE DIRECTOR WOULD HAVE CONFLICTING INTEREST ANNUALLY. |
| PART VI, SECTION B, LINE 15A/15B - OFFICERS COMPENSATION: | ON AN ANNUAL BASIS, THE BOARD WILL PERFORM A THOROUGH REVIEW TO DETERMINE SUITABLE COMPENSATION. THIS PROCESS INCLUDES ALL OF THE FOLLOWING THREE ELEMENTS. ======================================================================= 1. REVIEW AND APPROVAL BY BOARD OF DIRECTORS: THE COMPENSATION OF EACH OFFICER IS REVIEWED AND APPROVED BY THE BOARD OF DIRECTORS, PROVIDED THAT PERSONS WITH CONFLICTS OF INTEREST WITH RESPECT TO THE COMPENSATION ARRANGEMENT AT ISSUE ARE NOT INVOLVED IN THIS REVIEW AND APPROVAL. EACH OFFICER'S PERFORMANCE IS EVALUATED BASED ON HIS OR HER JOB RESPONSIBILITIES, AND INTERNAL AND EXTERNAL GOALS SET IN THE PREVIOUS YEAR. 2. REVIEW OF "COMPARABLE COMPENSATION" DATA: THE COMPENSATION OF EACH OFFICER IS REVIEWED AND APPROVED USING DATA AS TO COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS. COMPARABLE DATA ARE COMPILED BY THE FOUNDATION'S CHIEF FINANCIAL OFFICER AND/OR BY OUTSIDE COMPENSATION CONSULTANTS. COMPARABILITY DATA CAN INCLUDE COMPENSATION DATA FROM IRS FORM 990'S OF SIMILAR ORGANIZATIONS, PUBLISHED COMPENSATION SURVEYS, STUDIES AND GUIDES, AND OTHER SOURCES DEEMED APPROPRIATE AT THE TIME. 3. DOCUMENTATION AND RECORDKEEEPING: THERE IS CONTEMPORANEOUS DOCUMENTATION AND RECORDKEEPING WITH RESPECT TO THE DELIBERATIONS AND DECISIONS REGARDING THE COMPENSATION AGREEMENT. THE RECORD IS KEPT BY THE SECRETARY OF THE FOUNDATION. |
| PART VI, SECTION C, LINE19-AVAILABILTY OF DOCUMENTS, POLICIES, AND F/S: | THE FOUNDATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. THE FINANCIAL STATEMENTS ARE ALSO AVAILABLE ON THE FOUNDATION'S WEBSITE. |
| PART IX, LINE 26, JOINT COSTS ALLOCATION: | NFCR IS COMMITTED TO EFFICIENCY AND TRANSPARENCY. FOR MORE THAN 40 YEARS, NFCR HAS BEEN COMMUNICATING WITH SUPPORTERS, DONORS, AND PROSPECTIVE DONORS BY POSTAL MAIL, EMAIL, PHONE, WEBSITE AND OTHER MEANS, BOTH TO REQUEST CONTRIBUTIONS AND TO EDUCATE THE PUBLIC, THEREBY UPHOLDING NFCR'S MISSION STATEMENT ABOUT CANCER AND UPHOLD ITS MISSION, AND AT THE SAME TIME TO PROVIDE FUNDRAISING OPPORTUNITIES. THE COSTS RELATED TO THESE JOINT ACTIVITIES ARE ALLOCATED, THEREBY UPHOLDING NFCR'S MISSION STATEMENT (TO SUPPORT CANCER RESEARCH AND PUBLIC EDUCATION RELATING TO THE PREVENTION, EARLY DIAGNOSIS, BETTER TREATMENTS AND ULTIMATELY, A CURE FOR CANCER). THESE FREE PUBLICATIONS ARE SENT TO TENS OF MILLIONS OF FAMILIES AND INCLUDE MATERIALS SUCH AS EARLY DETECTION GUIDES, CHILDHOOD CANCER CHARTS, CANCER PREVENTION KITS AND RECIPES FOR HEALTHY LIVING. AS A RESULT, IN ACCORDANCE WITH THE FINANCIAL ACCOUNTING STANDARDS BOARD (FASB) GUIDELINES SOP 98-2 (ASC 958-720), WE ALLOCATE A PORTION OF OUR DIRECT MAIL COST TO PROGRAM SERVICES AND TO FUNDRAISING. |
| Software ID: | |
| Software Version: |